Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$273.29 USD

273.29
552,903

+1.58 (0.58%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $273.28 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification

by Zacks Equity Research

QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.

Zacks Equity Research

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Henry Schein (HSIC) Extends Partnership With Special Olympics

by Zacks Equity Research

Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.

Zacks Equity Research

Zacks.com featured highlights BellRing Brands, ResMed, NVIDIA and Transdigm

by Zacks Equity Research

BellRing Brands, ResMed, NVIDIA and Transdigm have been highlighted in this Screen of The Week article.

Zacks Equity Research

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.

Zacks Equity Research

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

by Zacks Equity Research

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.

Zacks Equity Research

QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus

by Zacks Equity Research

QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.

Tirthankar Chakraborty headshot

4 Top Stocks to Invest in for Astounding Earnings Growth

by Tirthankar Chakraborty

Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.

Zacks Equity Research

QIAGEN (QGEN) to Enhance Forensics With New Partnership

by Zacks Equity Research

QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.

Zacks Equity Research

Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised

by Zacks Equity Research

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Zacks Equity Research

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Nalak Das headshot

U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks

by Nalak Das

We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.

Zacks Equity Research

Teleflex (TFX) Expands Vascular Access Portfolio With New Launch

by Zacks Equity Research

Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.

Zacks Equity Research

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Zacks Equity Research

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

by Zacks Equity Research

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Zacks Equity Research

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

Zacks Equity Research

STERIS (STE) Q4 Earnings Match Estimates, Margins Contract

by Zacks Equity Research

STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.

Zacks Equity Research

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

by Zacks Equity Research

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

by Zacks Equity Research

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.

Zacks Equity Research

Zacks.com featured highlights include ResMed, Booz Allen Hamilton and Kontoor Brands

by Zacks Equity Research

ResMed, Booz Allen Hamilton and Kontoor Brands have been highlighted in this Screen of The Week article.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Zacks Equity Research

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

by Zacks Equity Research

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Zacks Equity Research

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.